TABLE 2.

Patient characteristics and outcomes of infections treated with cefiderocol or ceftazidime-avibactam + aztreonam

Patients treated with cefiderocol
Patient	Age, Sex	Co-morbidities	VIM infection site	Pathogens identified	Duration of cefiderocol treatment (d)	Co-administration of amikacin	Treatment outcome (determined by)
1	38, female	None	Bacteremia, neck wound	Klebsiella pneumoniae (VIM), Pseudomonas aeruginosa (wound only)	17	Yes (15 d)	Success (clearance of bacteremia, resolution of fevers)
2a	30, male	None	Bacteremia, R arm	Klebsiella pneumoniae (VIM), Serratia marcescens (VIM)	9	Yes (4 d)	Failure (persistent fevers, persistent bacteremia, recovery of cefiderocol resistant-Klebsiella pneumoniae from blood)
3	67, male	HTN, diabetes	L lower extremity	Klebsiella pneumoniae (VIM), Ochrobactrum anthropi	12	Yes (6 d)	Failure (persistent fevers, recovery of cefiderocol resistant-Klebsiella pneumoniae from the same site)
4b	30, male	None	R lower extremity	Klebsiella pneumoniae (VIM), Pseudomonas aeruginosa	19	No	Success (resolution of fevers, clinical assessment of wound, subsequent tissue culture)
5	23, male	Diabetes	Bacteremia, neck wound	Klebsiella pneumoniae (VIM)	10	Yes (9 d)	Success (clearance of bacteremia)

^a Patient 2 is included in both lists as he was treated with cefiderocol and amikacin followed by aztreonam, ceftazidime-avibactam, and amikacin for salvage therapy. Although his infection improved with salvage therapy, he subsequently developed candidemia and an Aspergillus wound infection. He passed away after a transition of goals of care.

^b Patient 4 is included in both lists as he had multiple separate infections due to VIM-CROs during his hospitalization and received both cefiderocol and the combination of ceftazidime-avibactam and aztreonam at different times.

^c Patient 8 had two infections due to VIM-CROs, isolated 21 days apart, during his hospitalization for which he received two separate courses of ceftazidime-avibactam and aztreonam.